Tools and Technology
Gefitinib for Advanced NSCLC Patients With EGFR Mutation
Karen J. Oishi, MSN, APRN, ANP-BC, GNP-BC, OCN®
From University of Texas MD
Anderson Cancer Center, Houston, Texas
The author has no potential conflicts of interest to disclose.
Correspondence to Karen J. Oishi, MSN, APRN, ANP-BC, GNP-BC, OCN, University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd, Unit 432, Houston, TX 77030. E-mail: koishi@mdanderson.org
J Adv Pract Oncol 2011;2:46–48 |
DOI: 10.6004/jadpro.2011.2.1.5 |
© 2011 Harborside Press®
For access to the full length article, please
sign in.
